Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...
COMBIVENT RESPIMAT (ipratropium bromide and albuterol) propellant-free MDI by Boehringer Ingelheim Boehringer Ingelheim announced that the FDA has approved Combivent Respimat (ipratropium bromide and ...
COMBIVENT RESPIMAT (ipratropium bromide and albuterol) propellant-free MDI by Boehringer Ingelheim Boehringer Ingelheim announced that Combivent Respimat (ipratropium bromide and albuterol) inhalation ...
Janette Seltzer developed a bad habit in the 1950s: She started smoking. “I started working when you were able to smoke and work, which didn't do me any favors,” Seltzer, a 76-year-old New York ...
As part of the company's commitment to chronic obstructive pulmonary disease (COPD) patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare ...
RIDGEFIELD, Conn., April 13 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" ...
ATLANTA, Georgia — Patients with chronic obstructive pulmonary disease (COPD) experience few adverse events and discontinuations when treated with an ipratropium plus albuterol inhalation spray (CVT-R ...
To earn CME related to this news article, click here. March 4, 2009 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to provide additional counseling information for ...
U.S. regulators have stamped an approval on a new inhaler that reduces the required inhalations per dose for Boehringer Ingelheim's treatment for chronic obstructive pulmonary disease (COPD), the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results